Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b pazopanib eye drops versus ranibizumab for neovascular age-related macular degeneration
2009-015106-19Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of pazopanib in exudative macular degeneration (2 arms), sponsored by GSK. Primary endpoint: Change from baseline in BCVA at Week 52. Started Nov 2009; status: completed.
02
Drugs
pazopanib
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2009-015106-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015106-19.